Biotech News
Related news
OTLKOutlook2026-05-28 20:00 EST
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
OTLKOutlook2026-04-23 20:05 EST
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
PRQRProQR Therapeutics2026-06-25 10:35 EST
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
OCGNOcugen2026-05-04 20:01 EST
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
TARSTarsus Pharmaceuticals2026-08-06 11:02 EST
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
IRIXIRIDEX2026-07-20 11:00 EST
Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering
LENZLenz Therapeutics Inc2026-07-06 12:15 EST
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
BLTEBelite Bio2026-04-27 12:00 EST
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit
LENZLenz Therapeutics Inc2026-08-04 20:05 EST
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
EYPTEyePoint Pharmaceuticals2026-09-16 11:00 EST
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Outlook
Ophthalmic Bevacizumab Company Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for...
Recent company news
OTLKOutlook2026-09-11 11:00 EST
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
OTLKOutlook2026-09-10 13:10 EST
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
OTLKOutlook2026-08-27 20:05 EST
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
OTLKOutlook2026-08-27 13:01 EST
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
OTLKOutlook2026-08-14 11:15 EST
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
Stock data
- Close
- 0.68 USD
- Market cap
- 120.89M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States